In describing how they had decided to name cancer immunotherapy as the 2013 Breakthrough of the Year, the staff of Science magazine also copped to their doubts about whether they had picked the right scientific advance. Read More
As we get ready to say “goodbye” to what will go down as one of biotech’s best years in recent memory, the pundits are out in force putting forth their predictions about whether the sector can repeat this stellar performance. Also might we see some major turbulence in the sector that throws investors a few unanticipated “curve balls”? On this topic, the biotech team of analysts at Cowan & Co. has just published its annual list of “Top 10 Potential Surprises” for the New Year, which makes for good reading and “food for thought.” Read More
